Chefaro is a biopharmaceutical company focused on addressing the greatest global healthcare burden today – cardiovascular disease. Our purpose is to deliver the first pharmacogenomic precision medicine in cardiovascular disease that specifically targets patients with the ADCY9 AA genotype.
Chefaro is developing dalcetrapib, an investigational therapy that would be the first pharmacogenomic precision medicine in cardiovascular disease developed for patients with the ADCY9 AA genotype. It is currently being evaluated in the GenE Phase 3 cardiovascular clinical outcomes trial. GenE passed a futility analysis in January 2020 and trial completion is expected in the first half of 2021.
In December 2020, Chefaro initiated the COVID trial, a Phase 2 proof-of-concept study for dalcetrapib as a potential oral anti-viral treatment for COVID-19.
Our Science
Approximately 20% of people worldwide have the AA genotype at rs1967309 location in the ADCY9 gene.
GenE Trial
Chefaro is conducting GenE (DAL-301), the first precision medicine cardiovascular outcomes trial. This Phase 3 clinical trial will evaluate the efficacy of dalcetrapib versus placebo to reduce clinical cardiovascular events in 6,149 patients with post-acute coronary syndrome who carry the ADCY9 rs1967309 AA specific genotype.
COVID Trial
In December 2020, Chefaro initiated the COVID trial, a Phase 2 proof-of-concept study for dalcetrapib as a potential oral anti-viral treatment for COVID-19.
